ArticlePloS one2026
The prevalence, prevention, and treatment of cardiovascular diseases in Twelve African Countries (2014-2019): An analysis of the World Health Organisation STEPwise approach to chronic disease risk factor surveillance.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCardiovascular diseases (CVDs) are responsible for nearly a third of deaths globally. We conducted this study to understand the prevalence of history of CVDs, their prevention and treatment in twelve African countries using the World Health Organization STEPwise Approach to Surveillance (WHO STEPS) data.
methodsWe used secondary STEPS data extracted from 12 African countries between 2014 and 2019. CVD was defined as a self-reported history of heart attack, angina, or stroke. Weighted percentages, counts, weighted odds ratios (OR), and the corresponding 95% confidence intervals (95%CI) were computed using the R software. We fitted logistic regression models to select the predictor variables from a regression model for CVD prevalence, CVD prevention and CVD treatment binary endpoints.
resultsAmongst 60,294 individuals, the prevalence of CVD was 5%. The CVD prevalence was higher in older individuals, females, individuals with hypertension, smokers, people with high salt intake, and in certain countries. Eleven percent of the 23,630 individuals at high risk of CVD (≥40 years) but without a history of the disease received CVD prevention treatment. Amongst the 2,895 persons with CVDs, 22% received treatment and counselling for CVD: 34% (n = 215) receiving aspirin, 32% (n = 202) counselling for CVD risk factors, 11% (n = 66) statins, and 24% (n = 148) both statins and aspirin. The uptake of CVD treatment varied by hypertension status, sex, age and country.
conclusionThe prevalence of CVD was relatively low and CVD treatment uptake was sub-optimal. Concerted efforts must be made to accelerate the diagnosis and expand treatment for CVDs in Africa if to curtail untimely deaths attributable to CVDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.